Cellosaurus SU.86.86 (CVCL_3881)

Cell line name SU.86.86
Synonyms SU 86.86; SU-86-86; Su-86-86; SU86.86; SU86-86; SU86_86; Su86_86; SU8686; SU.86
Accession CVCL_3881
Resource Identification Initiative To cite this cell line use: SU.86.86 (RRID:CVCL_3881)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Doubling time: 48 hours (PubMed=25984343).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Metabolome analysis.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: Su_86_96; In Cosmic 913314.
Misspelling: SU-88-86; In Cosmic 873003.
Disease Pancreatic adenocarcinoma (NCIt: C8294)
Derived from metastatic site: Liver.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10,11
D13S31711,12
D16S53911,13
D18S519
D21S1130
D3S135814,19
D5S8187,13
D7S8208,11
D8S117912,15
FGA21,22
Penta D9,13
Penta E12
TH019.3
TPOX8
vWA17
Web pages http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=SU.86.86
Publications

PubMed=3264833; DOI=10.1007/BF02624187
Drucker B.J., Marincola F.M., Siao D.Y., Donlon T.A., Bangs C.D., Holder W.D. Jr.
A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice.
In Vitro Cell. Dev. Biol. 24:1179-1187(1988)

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4
Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
Am. J. Pathol. 154:525-536(1999)

PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159
Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L., Veltman J.A., van Kessel A.G., Hoglund M.
Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.
Cancer Res. 64:3052-3059(2004)

PubMed=15688027; DOI=10.1038/sj.onc.1208383
Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H., Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.
Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.
Oncogene 24:1794-1801(2005)

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x
Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Cancer Sci. 99:986-994(2008)

PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963
Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J.
Phenotype and genotype of pancreatic cancer cell lines.
Pancreas 39:425-435(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25167228; DOI=10.1038/bjc.2014.475
Hamidi H., Lu M., Chau K., Anderson L., Fejzo M., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Br. J. Cancer 111:1788-1801(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26216984; DOI=10.1073/pnas.1501605112
Daemen A., Peterson D., Sahu N., McCord R., Du X., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)

PubMed=27259358; DOI=10.1074/mcp.M116.058313
Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J., Daly R.J.
Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.
Mol. Cell. Proteomics 15:2671-2685(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections ATCC; CRL-1837
IZSLER; BS TCL 180
Cell line databases/resources CCLE; SU8686_PANCREAS
CGH-DB; 183-1
CGH-DB; 9282-4
Cosmic-CLP; 1240218
GDSC; 1240218
LINCS_LDP; LCL-1747
SKY/M-FISH/CGH; 2000
Ontologies BTO; BTO:0001904
CLO; CLO_0009150
EFO; EFO_0006494
Biological sample resources BioSample; SAMN03472014
Gene expression databases GEO; GSM206545
GEO; GSM621901
GEO; GSM784693
GEO; GSM887650
GEO; GSM888742
GEO; GSM1024414
GEO; GSM1374903
GEO; GSM1435693
GEO; GSM1435694
GEO; GSM1435695
GEO; GSM1670481
Polymorphism and mutation databases Cosmic; 707252
Cosmic; 868244
Cosmic; 873003
Cosmic; 913314
Cosmic; 922250
Cosmic; 923172
Cosmic; 932522
Cosmic; 949237
Cosmic; 1006362
Cosmic; 1066203
Cosmic; 1122349
Cosmic; 1218879
Cosmic; 1358486
Cosmic; 1518237
Cosmic; 1644315
Cosmic; 1995645
Cosmic; 2434090
Proteomic databases PRIDE; PXD003198